Avalo Therapeutics, Inc.
AVTXReported to SECin USCIK 0001534120Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 36. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Sullivan Christopher RyanChief Financial Officer | Option exercise | nothing paid12,394 shares | Sep 18, 2026 | Sullivan Christopher RyanChief Financial Officer | nothing paid | Option exercise | 12,394 | Sep 18, 2026 |
| Sullivan Christopher RyanChief Financial Officer | Open-market sell | $202,43712,394 shares | Sep 18, 2026 | Sullivan Christopher RyanChief Financial Officer | $202,437 | Open-market sell | 12,394 | Sep 18, 2026 |
| Sullivan Christopher RyanChief Financial Officer | Option exercise | $122,45312,394 shares | Sep 18, 2026 | Sullivan Christopher RyanChief Financial Officer | $122,453 | Option exercise | 12,394 | Sep 18, 2026 |
| Sullivan Christopher RyanChief Financial Officer | Option exercise | nothing paid10,185 shares | Sep 11, 2026 | Sullivan Christopher RyanChief Financial Officer | nothing paid | Option exercise | 10,185 | Sep 11, 2026 |
| Sullivan Christopher RyanChief Financial Officer | Open-market sell | $179,45710,185 shares | Sep 11, 2026 | Sullivan Christopher RyanChief Financial Officer | $179,457 | Open-market sell | 10,185 | Sep 11, 2026 |